|Videos|September 6, 2017

Who is the Target Population for Cabotegravir?

Author(s)Contagion&reg Editorial Staff

Alex Rinehart, PhD, identifies the target population for cabotegravir.

Alex Rinehart, PhD, Director, Global Prevention Strategy, ViiV Healthcare, explains who the target population is for cabotegravir. Dr. Rinehart stresses that essentially, anyone who is at risk for HIV can use cabotegravir as a preventive option against the virus.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Subscribe Now!

Who is the Target Population for Cabotegravir?

Newsletter

Related Content

HIV Spending for Fiscal Year 2026: The Latest Update

Congress Preserves Domestic HIV Funding in Final FY2026 Spending Deal

UTI Treatment: Tailoring Patient Education and the Role of Insurance Payers

CDC ACIP Workgroup Reviewing FDA-Approved HPV Vaccines

Assessing Social Determinants of Health with Treatment Failure In UTIs

Latest CME

‘REEL’ Time Patient Counseling™: Improving Quality of Life for Patients with Sickle Cell Disease – Disease Modifying Therapy Vs. Curative Approaches

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

22nd Annual Winter Lung Cancer Conference®

(COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Breaking the 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis Cycle: The Importance of Early Intervention

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Show Me the Data™ New Frontiers in the Treatment of Ovarian Cancer

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Community Practice Connections™: 16th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

Expert Illustrations and Commentaries™: Visualizing Glucocorticoid Receptor Modulation in Platinum-Resistant Ovarian Cancer—Looking at Novel Pathways With an Eye Toward the Future of Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

How Do I Identify MOGAD? Improving Outcomes Through Early Identification of Patients

3rd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Community Practice Connections™: 18th Annual New York GU Cancer Congress™

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 1)

Expert Illustrations & Commentaries™: Visualizing the Role of the Complement Pathway in Paroxysmal Nocturnal Hemoglobinuria

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Proactive Adverse Event Management for HER2+ BTC Treatments

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Molecular Testing and Personalized Strategies in Pancreatic Cancer: Targeting NRG1 and Rare Drivers With an Optimized Approach

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Optimizing Care for Patients With Tardive Dyskinesia

Collaborating Across the Continuum®: A Team-Based Approach to Earlier Detection and Smarter Treatment in LN

Cases and Conversations: Navigating the New Immunotherapy Era in Squamous Cell Anal Carcinoma

Show Me the Data™—Closing Clinical Gaps in Gastric and Esophageal Cancer: Advancing Targeted Treatment Strategies Across the Care Continuum

EnVision Summit

Medical Crossfire®: Menin Inhibitors in AML—Dissecting the Data to Define the Role

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Huntington Beach Symposia

22nd Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Community Practice Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice?

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

Burst CME™: Stepping Up Care for Patients With PAH

43rd Annual Miami Breast Cancer Conference®

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

19th Annual New York GU Cancers Congress™

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas